查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806205

人類微生物組市場（按類型、目標微生物組部位、應用和最終用戶）—2025-2030 年全球預測

Human Microbiome Market by Type, Target Microbiome Site, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年人類微生物組市場價值將達到 19.6 億美元，2025 年將成長至 24.1 億美元，複合年成長率為 24.00%，到 2030 年將達到 71.3 億美元。

主要市場統計數據
基準年2024年 19.6億美元
預計2025年 24.1億美元
預測年份 2030 71.3億美元
複合年成長率（%） 24.00%

全面介紹人類微生物組的基本作用、歷史演化和策略重要性，揭示人類微生物組概況

人類微生物組已從最初的小眾科學好奇心迅速發展成為理解人類健康、疾病預防和治療創新的基礎要素。本書全面闡述了人體內外複雜的微生物群落如何影響免疫調節、代謝調節和神經路徑。透過檢驗微生物組研究中的關鍵發現和重要里程碑，讀者將了解從早期培養為基礎的研究到高通量定序和多體學整合的歷程。

透過技術突破，制定政策並進行策略合作，以找到改變人類微生物組的轉捩點

人類微生物組快速演進的核心是最尖端科技、政策改革和新型共同研究模式所推動的變革性轉變。定序技術的最新進展，包括新世代平台和攜帶式照護現場設備，正在大幅縮短週轉時間和降低成本，實現即時微生物分析，並促進分散式診斷。

評估2025年美國貿易關稅對人類微生物組領域供應鏈、成本結構和創新動態的累積影響

2025年美國貿易關稅的實施，為人類微生物組領域帶來了複雜的挑戰與戰略考量。針對專用試劑、高精度定序設備和聚合酵素鏈鎖反應組件等關鍵投入的進口關稅，正對診斷設備和實驗室耗材的製造成本造成上行壓力。這些成本的上漲迫使製造商重新評估其供應鏈配置，並考慮在地採購和近岸外包策略，以減輕關稅波動的影響。

透過目標微生物組、場所、應用和最終用戶類型揭示關鍵細分洞察，以揭示多樣化的市場動態

詳細了解市場細分，可以明確人類微生物組價值鏈中成長機會和競爭壓力的交會點。按類型分類，市場包括抗生素（其在調節微生物種群方面持續發揮關鍵作用）和診斷設備（從高通量微生物組測序平台到基於PCR的快速檢測）。同時，以菊糖和寡糖為代表的益生元類別凸顯了目標基材在有益微生物營養支持中的重要性，而益生菌和合合益素（將活性培養物與支持性纖維混合）這一不斷發展的領域則為其提供了補充。

美洲、中東和非洲以及亞太地區的重點突出了地理趨勢和成長催化劑

微生物組應用、監管格局和研究投入的地區差異，驅動了全球微生物組市場的不同成長軌跡。在美洲，強大的精準醫療基礎設施和領先的學術中心正在加速臨床檢驗研究，尤其是在腸道和皮膚微生物組領域。在北美，創業投資和支持性監管指南的結合，促進了專注於創新療法和直接面對消費者的診斷產品的新興企業的活動。

分析產業領袖之間的策略聯盟和技術創新如何塑造人類微生物組的競爭態勢

人類微生物組領域的競爭格局正由多元化的參與者塑造，從大型製藥企業到專業的生物技術公司，再到敏捷的診斷創新者。傳統醫療保健公司正在透過收購微生物療法新興企業以及與學術中心合作來擴展其產品線，以檢驗微生物組干預的新適應症。同時，早期公司正在建立策略夥伴關係關係，以加速臨床開發，並在代謝感染疾病等標靶治療領域中獲得發展。

提供可行的策略建議，幫助產業領導者最佳化投資、降低風險並利用新機會

為了應對人類微生物組生態系統的複雜性並最大化創新投資回報，產業領導者應採取多管齊下的策略方針。首先，透過整合診斷、補充劑和治療產品來實現產品系列的多元化，可以減少對單一收益來源的依賴，並創造跨臨床和消費者管道的交叉銷售機會。此外，還可以透過與受託研究機構和學術聯盟合作，加速生物標記的發現和臨床檢驗，進一步強化這種整體定位。

結合專家初步訪談、二次資料分析和高階分析架構的調查方法提供了可靠的見解

本執行摘要所依據的調查方法整合了多層資料收集和分析，以確保獲得可靠且可操作的見解。主要研究包括對高階主管、學術思想領袖和臨床實踐者的深入訪談，以獲得關於技術進步、監管趨勢和商業策略的第一手觀點。這些定性資訊也得到了二次研究的補充，包括對已發表文獻、監管指南文件、行業白皮書和專利申請的全面回顧。

全面的人類微生物組執行摘要摘要了相關人員的主要趨勢和前進方向

總而言之，充滿活力的人類微生物組研究和商業化領域為診斷、治療和健康應用領域的創新提供了前所未有的機會。本摘要闡明了微生物群落的根本性作用，強調了技術和政策的變革性轉變，並分析了近期貿易關稅對成本結構和供應鏈的影響。將這些研究結果納入詳細的細分領域和區域框架，有助於相關人員更好地根據市場現狀和患者需求調整策略。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 針對特定疾病的標靶生物製藥快速開發
  • 使用基於人工智慧的代謝組學分析識別基於微生物組的診斷生物標記
  • 新一代益生菌在牙周病口腔微生物組調控的應用進展
  • 利用皮膚微生物組定序和分析開發個人化護膚方案
  • 旨在增強腸道屏障功能和免疫力的合成微生物群落的出現
  • 擴大兒科微生物組研究，重點關注兒童早期健康和發育結果
  • 製藥和微生物組Start-Ups將合作研究拓展至新藥研發平台
  • 基於個人腸道微生物組分析的精準營養解決方案的採用率不斷提高
  • 將糞便微生物移植納入胃腸道疾病的標準化通訊協定
  • 監管機構發布生物製劑核准和品質標準新指南

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 人體微生物組市場（依類型）

  • 抗生素
  • 診斷設備
    • 微生物定序序裝置
    • 基於PCR的診斷
  • 益生元
    • 菊糖
    • 寡糖
  • 益生菌
  • 合益素

9. 人類微生物組市場目標微生物組站點

  • 腸道菌叢
  • 鼻腔和呼吸道微生物群
  • 口腔微生物群
  • 皮膚微生物群
  • 陰道微生物群

第 10 章：人體微生物組市場（依應用）

  • 診斷
    • 生物標記發現
    • 臨床診斷
    • 伴隨診斷
  • 補充
  • 治療藥物
    • 胃腸道疾病
    • 感染疾病
    • 代謝紊亂
    • 皮膚病

第 11 章：人體微生物組市場（依最終用戶分類）

  • 診斷實驗室
  • 居家照護環境
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

12. 美國人類微生物組市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲地區人類微生物媒體市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14. 亞太地區人類微生物組市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • DuPont de Nemours, Inc.
    • Ferring BV
    • AOBiome, LLC
    • Axial Therapeutics, Inc.
    • BioHM Health Inc.
    • BiomeSense, Inc.
    • Enterome Bioscience
    • Finch Therapeutics Group, Inc.
    • Illumina, Inc.
    • Infinant Health Inc.
    • Intralytix, Inc.
    • Merck KGaA
    • Metabiomics Corporation
    • Osel Inc.
    • Pendulum Therapeutics
    • Synlogic, Inc.
    • Synthetic Biologics, Inc.
    • Viome Life Sciences, Inc.
    • Yakult Honsha Co., Ltd.

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-430D42AA0FCD

The Human Microbiome Market was valued at USD 1.96 billion in 2024 and is projected to grow to USD 2.41 billion in 2025, with a CAGR of 24.00%, reaching USD 7.13 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.96 billion
Estimated Year [2025] USD 2.41 billion
Forecast Year [2030] USD 7.13 billion
CAGR (%) 24.00%

Uncovering the Human Microbiome Landscape Through a Comprehensive Introduction Highlighting Its Fundamental Roles, Historical Evolution, and Strategic Importance

The human microbiome has swiftly evolved from a niche scientific curiosity to a foundational element in understanding human health, disease prevention, and therapeutic innovation. This comprehensive introduction unpacks how the complex communities of microorganisms residing in and on the human body influence immune modulation, metabolic regulation, and neurological pathways. By examining seminal discoveries and key milestones in microbiome research, readers can appreciate the journey from early culture-based studies to high-throughput sequencing and multi-omics integrations.

Transitions within this field underscore the importance of interdisciplinary collaboration, as clinicians, microbiologists, bioinformaticians, and industry stakeholders converge to translate laboratory insights into real-world applications. This section establishes the essential context for the subsequent analysis by highlighting the microbiome's multifaceted role in diagnostics, supplements, and therapeutics. It sets the stage for exploring how foundational knowledge of microbial interactions is now driving precision medicine, personalized nutrition strategies, and novel drug discovery paradigms.

By grounding the executive summary in both historical perspective and contemporary relevance, this introduction ensures that decision-makers, investors, and research leaders gain a cohesive understanding of why the human microbiome continues to redefine the boundaries of healthcare innovation.

Identifying the Transformative Shifts Revolutionizing the Human Microbiome Landscape with Technological Breakthroughs Policy Advances and Strategic Collaborations

At the heart of the human microbiome's rapid evolution are transformative shifts fueled by cutting-edge technologies, policy reforms, and novel collaborative models. Recent advancements in sequencing technologies, including next-generation platforms and portable point-of-care devices, have drastically reduced turnaround times and costs, enabling real-time microbial profiling and fostering decentralized diagnostics.

Parallel to these technological breakthroughs, regulatory bodies have begun to establish clearer frameworks for microbiome-based products, particularly in the arenas of companion diagnostics and live biotherapeutic approvals. Evolving guidelines for clinical trials and quality assurance are streamlining pathways to market, incentivizing pharmaceutical and biotechnology entities to invest in pipeline expansion and strategic partnerships.

Equally impactful are cross-sector alliances that unite academic institutions, contract research organizations, and industry participants to co-develop standardized protocols for data sharing, analytical validation, and clinical applicability. These collaborations are redefining value chains, enabling stakeholders to transition from siloed research endeavors to integrated innovation ecosystems. Consequently, organizations that adapt to these shifts-by investing in agile methodologies, forging interdisciplinary alliances, and aligning with emergent regulations-are positioned to lead the next wave of microbiome discoveries.

Assessing the Cumulative Impact of 2025 United States Trade Tariffs on Supply Chains, Cost Structures, and Innovation Dynamics in Human Microbiome Sector

The implementation of United States trade tariffs in 2025 has introduced a complex array of challenges and strategic considerations for the human microbiome sector. Import duties on key inputs such as specialized reagents, high-precision sequencing instruments, and polymerase chain reaction components have exerted upward pressure on production costs for diagnostic devices and laboratory consumables. These cost inflations are prompting manufacturers to reevaluate supply chain configurations and consider localized sourcing or near-shoring strategies to mitigate exposure to tariff volatility.

Moreover, the cumulative effect of increased import duties has compelled stakeholders to scrutinize long-term partnerships with international suppliers, renegotiate contracts, and assess total landed costs for raw materials. In parallel, research and development budgets are being recalibrated to accommodate these additional expenses, which may impact the pace of innovation in areas such as live biotherapeutics, next-generation sequencing assays, and novel probiotic formulations.

Despite these headwinds, some organizations are leveraging tariff-driven disruption as an impetus for reshoring critical manufacturing processes and strengthening domestic supply resilience. By investing in local production of key reagents and equipment, companies can not only offset tariff burdens but also accelerate regulatory compliance timelines and reinforce quality control frameworks. Ultimately, the sector's ability to adapt procurement, production, and partnership strategies will determine how effectively it weathers the evolving trade landscape and sustains momentum in microbial research and commercialization.

Unveiling Critical Segmentation Insights by Type Target Microbiome Site Application and End User to Illuminate Diverse Market Dynamics

A granular understanding of market segmentation offers indispensable clarity into where growth opportunities and competitive pressures converge across the human microbiome value chain. By type, the market encompasses antibiotics, which continue to play a critical role in modulating microbial populations, as well as diagnostic devices that range from high-throughput microbiome sequencing platforms to rapid PCR-based assays. Meanwhile, the prebiotic category, anchored by inulin and oligosaccharides, underscores the importance of targeted substrates in nourishing beneficial microorganisms, complemented by the growing fields of probiotics and synbiotics that blend live cultures with supportive fibers.

Exploring the segmentation based on target microbiome site reveals distinct research and commercial pathways: the gut microbiome remains the largest focus of clinical and consumer interest, but substantial research initiatives now investigate nasal and respiratory, oral, skin, and vaginal microbial ecosystems. In parallel, application-based segmentation delineates three primary cohorts: diagnostics, which include early-stage biomarker discovery, clinical diagnostics, and companion diagnostic tools; supplements that range from functional foods to nutraceutical formulations; and therapeutics addressing gastrointestinal disorders, infectious diseases, metabolic syndromes, and dermatological conditions.

Lastly, end-user segmentation identifies diagnostic laboratories, home care settings, hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes as the principal conduits through which microbiome solutions reach the market. Together, these layered perspectives illuminate the nuanced interplay between scientific innovation, clinical utility, and commercial viability within the dynamic microbiome ecosystem.

Highlighting Key Regional Insights across the Americas Europe Middle East and Africa and Asia Pacific to Illuminate Geographic Trends and Growth Catalysts

Regional nuances in adoption, regulatory frameworks, and research investments have created differentiated trajectories for growth across the global microbiome landscape. In the Americas, robust infrastructure in precision medicine and the presence of leading academic centers have accelerated clinical validation studies, particularly in the gut and skin microbiome domains. The convergence of venture capital investment and supportive regulatory guidance in North America has catalyzed a surge of startup activity focused on innovative therapeutics and direct-to-consumer diagnostic offerings.

Turning to Europe, the Middle East, and Africa, a mosaic of regulatory harmonization efforts and collaborative initiatives between public research institutions and private firms is fostering a fertile environment for microbiome research. Policymakers across the European Union are advancing frameworks for live biotherapeutic products, while Middle Eastern markets are exploring strategic partnerships to integrate microbiome technologies into national health programs. Meanwhile, select African research consortia are leveraging microbial diversity studies to address endemic health challenges and unlock novel bioactive compounds.

In the Asia-Pacific region, rapid digital health adoption, expansive population cohorts, and growing healthcare expenditures are fueling interest in both therapeutic interventions and functional foods designed to optimize microbial health. Governments and industry players are forging consortia to drive large-scale population studies, while regional manufacturers are scaling up production of prebiotic and probiotic formulations to serve local and export markets. These regional insights underscore the importance of tailored strategies that align with unique regulatory, clinical, and consumer contexts.

Analyzing Leading Industry Participants Strategies Collaborations and Technological Innovations Shaping Competitive Dynamics within the Human Microbiome

The competitive landscape of the human microbiome sector is defined by a diverse array of actors, ranging from established pharmaceutical giants to specialized biotechnology firms and agile diagnostic device innovators. Legacy healthcare organizations are expanding their pipelines through acquisitions of microbial therapeutics startups and collaborations with academic centers to validate novel indications for microbiome interventions. Concurrently, early-stage firms are securing strategic partnerships to accelerate clinical development and gain traction in target therapeutic areas such as metabolic disorders and infectious diseases.

Diagnostic device manufacturers, leveraging capabilities in high-throughput sequencing and PCR-based platforms, are investing in integrated solutions that combine sample-to-result workflows with advanced bioinformatics analytics. These endeavors are supported by contract research organizations that specialize in microbial assay validation and regulatory consulting, creating an ecosystem that facilitates faster market entry and quality compliance.

Supplement providers and nutraceutical companies are differentiating through proprietary formulations of prebiotics, probiotics, and synbiotics, often backed by human clinical trials and consumer wellness studies. This convergence of scientific rigor and consumer engagement is intensifying competition in the direct-to-consumer segment, compelling players to invest in digital health tools and personalized nutrition platforms. Collectively, the strategic maneuvers of these companies-spanning mergers, licensing agreements, and co-development programs-are reshaping the contours of competitive advantage within the microbiome arena.

Delivering Actionable Strategic Recommendations to Empower Industry Leaders Optimize Investments Mitigate Risks and Capitalize on Emerging Opportunities

To navigate the complexities of the human microbiome ecosystem and maximize return on innovation investments, industry leaders should pursue a multi-pronged strategic approach. First, diversifying product portfolios by integrating diagnostics, supplements, and therapeutics will reduce reliance on any single revenue stream and enable cross-selling opportunities across clinical and consumer channels. This holistic positioning can be further strengthened by forging alliances with contract research organizations and academic consortia to accelerate biomarker discovery and clinical validation.

Second, investing in regional manufacturing footprints and supply chain resilience is critical in light of evolving trade policies and input cost fluctuations. Establishing localized reagent production and scalable fermentation capabilities will safeguard against external disruptions while optimizing total cost of ownership and regulatory compliance timelines.

Third, adopting advanced analytical frameworks, including machine learning-driven microbial signature analysis and digital health integrations, will empower real-time decision-making and personalized treatment protocols. Combining these capabilities with patient engagement platforms enhances data collection and outcomes monitoring, fostering long-term value generation.

Finally, proactive engagement with regulatory stakeholders and participation in industry standardization initiatives will streamline approval pathways and bolster stakeholder confidence. By championing best practices for quality assurance and data transparency, organizations can solidify their reputations as trusted partners in the evolving human microbiome field.

Presenting a Research Methodology Combining Primary Expert Interviews Secondary Data Analysis and Advanced Analytical Frameworks to Ensure Robust Insights

The research methodology underpinning this executive summary integrates multiple layers of data collection and analysis to ensure robust, actionable insights. Primary research involved in-depth interviews with senior executives, academic thought leaders, and clinical practitioners to capture firsthand perspectives on technological advancements, regulatory trends, and commercial strategies. These qualitative inputs were complemented by secondary research, which encompassed a comprehensive review of published literature, regulatory guidance documents, industry white papers, and patent filings.

Data triangulation techniques were employed to validate emerging trends and reconcile discrepancies between conflicting data points. Advanced analytical frameworks, including cluster analysis of segmentation variables and scenario planning around trade tariff impacts, were applied to deepen the understanding of market dynamics. Comparative analyses across geographic regions and end-user categories further enriched the contextual narrative, enabling a balanced assessment of growth drivers and potential inhibitors.

Finally, an expert validation process engaged a panel of multidisciplinary advisors to review key findings, verify assumptions, and refine strategic recommendations. This rigorous, multi-stage approach ensures that the insights presented herein are grounded in empirical evidence and reflect the latest developments within the human microbiome landscape.

Summarizing the Comprehensive Human Microbiome Executive Summary to Reinforce Strategic Takeaways Critical Trends and the Path Forward for Stakeholders

In conclusion, the dynamic field of human microbiome research and commercialization offers unprecedented opportunities for innovation across diagnostics, therapeutics, and wellness applications. This summary has illuminated the foundational roles of microbial communities, highlighted transformative shifts in technology and policy, and dissected the implications of recent trade tariffs on cost structures and supply chains. By contextualizing these findings within detailed segmentation and regional frameworks, stakeholders can better align their strategies with market realities and patient needs.

The competitive landscape is being reshaped by strategic partnerships, mergers, and technological integrations that drive differentiation and accelerate time to market. Forward-thinking organizations that embrace diversified portfolios, invest in supply chain resilience, and leverage advanced analytics will be poised to lead the next wave of microbiome breakthroughs.

As this sector continues to evolve, ongoing collaboration between industry, academia, and regulatory authorities will be critical to translating scientific discovery into tangible health outcomes. The pathways outlined in this executive summary offer a strategic blueprint for navigating complexity and capitalizing on the transformative potential of the human microbiome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Surge in development of targeted live biotherapeutic products for specific diseases
  • 5.2. Utilization of AI-driven metabolomic analysis to identify microbiome-based diagnostic biomarkers
  • 5.3. Advances in oral microbiome modulation via next-generation probiotics targeting periodontal diseases
  • 5.4. Development of personalized skincare formulations leveraging skin microbiome sequencing and analytics
  • 5.5. Emergence of synthetic microbial consortia engineered for enhanced gut barrier function and immunity
  • 5.6. Expansion of pediatric microbiome research focusing on early-life health and developmental outcomes
  • 5.7. Growth in collaborations between pharma and microbiome startups for novel drug discovery platforms
  • 5.8. Increasing adoption of precision nutrition solutions based on individual gut microbiome profiling
  • 5.9. Integration of fecal microbiota transplantation with standardized protocols for gastrointestinal disorders
  • 5.10. Regulatory agencies issuing new guidelines for live biotherapeutic product approval and quality standards

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Human Microbiome Market, by Type

  • 8.1. Introduction
  • 8.2. Antibiotics
  • 8.3. Diagnostic Devices
    • 8.3.1. Microbiome Sequencing Devices
    • 8.3.2. PCR-Based Diagnostics
  • 8.4. Prebiotics
    • 8.4.1. Inulin
    • 8.4.2. Oligosaccharides
  • 8.5. Probiotics
  • 8.6. Synbiotics

9. Human Microbiome Market, by Target Microbiome Site

  • 9.1. Introduction
  • 9.2. Gut Microbiome
  • 9.3. Nasal & Respiratory Microbiome
  • 9.4. Oral Microbiome
  • 9.5. Skin Microbiome
  • 9.6. Vaginal Microbiome

10. Human Microbiome Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostics
    • 10.2.1. Biomarker Discovery
    • 10.2.2. Clinical Diagnostics
    • 10.2.3. Companion Diagnostics
  • 10.3. Supplements
  • 10.4. Therapeutics
    • 10.4.1. Gastrointestinal Disorders
    • 10.4.2. Infections
    • 10.4.3. Metabolic Disorders
    • 10.4.4. Skin Disorders

11. Human Microbiome Market, by End User

  • 11.1. Introduction
  • 11.2. Diagnostic Laboratories
  • 11.3. Home Care Settings
  • 11.4. Hospitals & Clinics
  • 11.5. Pharmaceutical & Biotechnology Companies
  • 11.6. Research Institutes

12. Americas Human Microbiome Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Human Microbiome Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Human Microbiome Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. DuPont de Nemours, Inc.
    • 15.3.2. Ferring B.V.
    • 15.3.3. AOBiome, LLC
    • 15.3.4. Axial Therapeutics, Inc.
    • 15.3.5. BioHM Health Inc.
    • 15.3.6. BiomeSense, Inc.
    • 15.3.7. Enterome Bioscience
    • 15.3.8. Finch Therapeutics Group, Inc.
    • 15.3.9. Illumina, Inc.
    • 15.3.10. Infinant Health Inc.
    • 15.3.11. Intralytix, Inc.
    • 15.3.12. Merck KGaA
    • 15.3.13. Metabiomics Corporation
    • 15.3.14. Osel Inc.
    • 15.3.15. Pendulum Therapeutics
    • 15.3.16. Synlogic, Inc.
    • 15.3.17. Synthetic Biologics, Inc.
    • 15.3.18. Viome Life Sciences, Inc.
    • 15.3.19. Yakult Honsha Co., Ltd.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. HUMAN MICROBIOME MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. HUMAN MICROBIOME MARKET: RESEARCHAI
  • FIGURE 24. HUMAN MICROBIOME MARKET: RESEARCHSTATISTICS
  • FIGURE 25. HUMAN MICROBIOME MARKET: RESEARCHCONTACTS
  • FIGURE 26. HUMAN MICROBIOME MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. HUMAN MICROBIOME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 122. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 123. CANADA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 124. CANADA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 135. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 138. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 139. MEXICO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 140. MEXICO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 141. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 142. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 147. MEXICO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 148. MEXICO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 149. MEXICO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. MEXICO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 151. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 154. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 155. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 156. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 157. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 158. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 159. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 163. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 164. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 165. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 167. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 170. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 171. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 172. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 173. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 174. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 175. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 179. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 180. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 181. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 217. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 221. GERMANY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 223. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 225. GERMANY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. GERMANY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 228. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 229. GERMANY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 230. GERMANY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 231. GERMANY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GERMANY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 233. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 236. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 237. FRANCE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 238. FRANCE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 239. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 240. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 241. FRANCE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. FRANCE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 243. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 245. FRANCE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 246. FRANCE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 247. FRANCE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. FRANCE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 249. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 253. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 254. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 255. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 257. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 259. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 260. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 261. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 262. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 263. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 265. ITALY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. ITALY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 268. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 269. ITALY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 270. ITALY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 271. ITALY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 272. ITALY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 273. ITALY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. ITALY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 275. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 276. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 277. ITALY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 279. ITALY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 281. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 284. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 285. SPAIN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 287. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 289. SPAIN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 293. SPAIN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 294. SPAIN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 295. SPAIN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. SPAIN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 309. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 316. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 318. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 320. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 324. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 326. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 332. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 334. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2024 (USD MILLION)
  • TABLE 336. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 338. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 340. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 341. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 342. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 343. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 345. DENMARK HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. DENMARK HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 347. DENMARK HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 348. DENMARK HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC